Next FDA user fee deal is under review at the White House
The White House is examining a deal recently reached by the FDA and the biopharma industry that sets the prescription drug user fees that the sector will pay the agency from 2028 through 2032, sources ...
May 29, 2026 01:30 PM EDT FDA+ FDA's next fee deal, stacked with US incentives, is under White House review Zachary Brennan Senior Editor The White House is examining a deal recently reached by the FDA and the biopharma industry that sets the prescription drug user fees that the … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that